Escolar Documentos
Profissional Documentos
Cultura Documentos
Antiasthmatic Agents
Hans Michael Jennewein, Boehringer Ingelheim Pharma KG, Ingelheim/Rhein, Federal Republic of
Germany
Jorge Casals-Stenzel, Gauting-Königswiesen, Federal Republic of Germany
Kurt Schromm, Boehringer Ingelheim Pharma KG, Ingelheim/Rhein, Federal Republic of Germany
It does not play a role in the treatment of acute C4 , D4 , E4 and of leukotriene B4 . Zileuton is the
asthmatic attacks including severe asthma [96], most advanced 5-lipoxygenase inhibitor, which
[97]. Chemical structure: has been introduced into the therapy of asthma
in some countries.
5. Antileukotrienes
It has been shown that leukotrienes Montelukast sodium is a potent, selective
(→ Prostaglandins, Chap. 2.) play a funda- competitive antagonist for cysteinyl leukotriene
mental role in asthma. Especially the cystenyl receptors such as LTD4 . It is orally active and
leukotrienes are thought to be involved in the shows therapeutic effects in patients with asthma
pathophysiology of asthma. The leukotriene an- [101].
tagonists montelukast and zafirlukast are the Trade name: Singulair (Merck Frosst).
most prominent antileukotrienes which are reg-
istered or close to registration. Another possi- Zileuton [111406-87-2], (±)-N-(1-benzo-
bility is to inhibit the synthesis of leukotrienes. [b]thien-2-ylethyl)-N-hydroxyurea, C11 H12 N2 O2 S,
The key enzyme is 5-lipoxygenase which, when M r 236.29. Chemical structure:
inhibited, blocks the formation of leukotriene
20 Antiasthmatic Agents
33. K. H. Klingler, Arzneim. Forsch. 27 (1977) 4. 59. A. B. Draco, EP 43 807, 1982, US 4 419 364
34. A. A. G. Lewis (ed.): “Salbutamol,” Postgrad. 1983.
Med. J. 47 (1971) Suppl., 11 – 34. 60. N. Svedmyr, Scand. J. Respir. Dis. 101 (1977)
35. D. T. Collin, D. Hartley, D. Jack, L. H. C. Suppl. 125.
Lunts, J. C. Press, A. C. Ritchie, P. Toon, J. 61. J. W. Jenne in M. Stem (ed.): New Directions
Med. Chem. 13 (1970) 674. in Asthma, American College of Chest
36. Allen & Hanburys, GB 1200886, 1966. Physicians, Park Ridge, Ill., 1975, p. 391.
37. D. M. Aviado: Sympathomimetic Drugs, 62. E. Schmid, M. von Bubnoff, R. Taugner,
Charles C. Thomas, Springfield, Ill., USA, Arzneim. Forsch. 5 (1955) 194.
1970, p. 95. 63. W. Traube, Ber. Dtsch. Chem. Ges. 33 (1900)
38. R. H. F. Manske, T. B. Johnson, J. Am. Chem. 3035.
Soc. 51 (1929) 580. 64. H. Bredereck, A. Edenhofer, Chem. Ber. 88
39. A. Kraushaar, Ärztl. Wochenschr. 5 (1950) (1955) 1306.
779. 65. A. Lespagnol, J. Vanlerenberghe, L. Masse,
40. P. Ballmer, CH 266997, 1948; US 2558068, Bull. Soc. Pharm. Lille 2 (1948) 18.
1949. 66. L. Fabbrini, R. Cencioni, Farmaco Ed. Sci. 17
41. G. Engelhardt, Arzneim. Forsch. 26 (1976) (1962) 660.
1404. 67. H. J. Roth, Arch. Pharm. Ber. Dtsch. Pharm.
42. J. Keck, G. Krüger, K. Noll, H. Machleidt, Ges. 292 (1959) 234.
Arzneim. Forsch. 22 (1972) 861. 68. C. Graffner, G. Johnsson, J. Sjögren, Acta
43. Thomae, DE 1543928, 1966; DE 2157040, Pharm. Suec. 10 (1973) 425.
1971. 69. Gane’s Chem. Works, US 2715125, 1955.
44. G. Engelhardt et al., Arzneimittel-Forsch. 34 70. State Univ. Iowa, US 2575344, 1951.
(1984) 1612. 71. J. Blaisse, Bull. Soc. Chim. Fr. 16 (1949) 769.
45. J. Keck, G. Krüger, K. Noll, H. Machleidt, 72. A. Georges, J. Page, G. Duvernay, Therapie
Arzneim.-Forsch. 22 (1972) 861. 17 (1962) 211.
46. S. Kubo, Y. Kasé, T. Mijata, G. Kito, I. 73. A. Christiaens, BE 602888, 1961.
Uesaka, Arzneim. Forsch. 25 (1975) 1028. S. 74. W. M. Gold, Postgrad. Med. J. 51 (1975)
Kubo, I. Uesaka, I. Matsubara, T. Ishihara, Y. Suppl. 7, 53.
Kasé, Arzneim. Forsch. 27 (1977) 1433. 75. R. Bauer, S. Püschmann, H. Wick, Arzneim.
47. Hokuriku Pharm. Co., JP 7170337, 1971. Forsch. 26 (1976) 981.
48. J. R. Wardell, D. F. Colella, M. S. Shetzline, 76. F. Chemnitius, J. Prakt. Chem. 116 (1927)
P. J. Fowler, J. Pharmacol. Exp. Ther. 189 276. W. Schneider, Arch. Pharm. Ber. Dtsch.
(1974) 167. Pharm. Ges. 284 (1951) 306.
49. C. Kaiser, D. F. Colella, M. S. Schwartz, E. 77. R. Bauer, F.-J. Kuhn, K. Stockhaus, H. Wick,
Garrey, J. R. Wardell, J. Med. Chem. 17 Arzneim. Forsch. 26 (1976) 974.
(1974) 49. 78. W. Schulz, R. Banholzer, K.-H. Pook,
50. H. Ida, Arzneimittel-Forsch. 26 (1976) 839, Arzneim. Forsch. 26 (1976) 960.
1337. 79. Boehringer Ingelheim GmbH, DE 1670048,
51. D. Faulds et al., Drugs 42 (1991) 115. 1966.
52. Yamanouchi, DE 2 305 092, 1973, 80. B. Disse et al., Life Sci 52 (1993) 537.
81. Boehringer Ingelheim, DE 3 931 041, 1991;
US 3 994 974, 1976.
EP 418 716, 1991.
53. S. Yamashita, M. Takai, Y. Yabuuchi, J.
82. J. V. Collins, T. J. H. Clark, D. Brown, J.
Pharm. Pharmacol. 30 (1978) 273.
Townsend, Q. J. Med. 44 (1975) 259.
54. S. Yoshizaki, K. Tanimura, S. Tamada, Y.
83. P. J. Barnes, J. Allerg. Clin. Immunol. 97
Yabuuchi, K. Nakugawa, J. Med. Chem. 19
(1996) 159.
(1976) 1138.
84. J. M. Cox, R. M. Mowers, DICP Ann.
55. H. Minatoya, B. F. Tullar, Pharmacologist 16
Pharmacother. 23 (1989) 597.
(1974) 211. H. Minatoya, J. Pharmacol. Exp.
85. W. Pedersen, D. Prahl, Allergy 42 (1987) 272.
Ther. 206 (1979) 515.
86. R. F. Wiley et al., Chest 76 (1982) 61.
56. Sterling Drug Inc., DE 2015573, 1970.
87. O. Sebroos et al., Allergy 49 (1994) 833.
57. L. A. Svensson, Pharm. Res. 1985, 156.
88. F. E. McCarthy, Lancet 1989i, 380.
58. O. A. Torsten, L. A. Svensson, Pharm. Res. 89. S. M. Holliday, Drugs 47 (1994) 318.
1984, 19. 90. M. Johnson, Lung 168 (1990) Suppl., 115.
22 Antiasthmatic Agents
91. R. N. Brogden, D. Faulds, Drug 42 (1991) 97. T. L. Petty et al., Am. Rev. Respir. Dis. 139
895. (1989) 694.
92. Glaxo, US 4 992 474, 1991. 98. R. N. Brogden, E. M. Sorkin, Drugs 45 (1993)
93. Drugs of the Future II (1977) 284. 693.
94. Pfizer, DE 2 204 195, 1972, US 3 700 681, 99. Ann. Drug Data Rep. 18 (1996) 789.
1972. 100. I. S. Kelloway, Ann. Pharmacother. 31 (1997)
95. M. K. Church, Med. Actual 14 (1978) 281. 1012.
96. S. Murphy, H. W. Kelly, Drug Intell. Clin. 101. Drugs of the Future 22 (1997) 1103.
Pharm. 21 (1987) 22. 102. Drugs of the Future 18 (1993) 616.
103. Ann. Drug Data Rep. 19 (1997) 609.